Agreed. And at the time of purchase there were a lot of people who bashed the move to stop P trials and buy B. Turned out to be a very wise decision. Listening to Menon to start P back up again was not. Hence why Menon got the boot IMO. Menon had nothing to do with B. Nobody at IPIX created it. The market doesn’t comprehend biomemetics and the massive potential. Not yet.
The market is a shallow thinker who gets it right a lot of the time because most people are shallow investors. Easily rattled by any sign of weakness. Fear based trading. Knowing the history of a compound can help alleviate those fears. How it was created. Who created it. Seeing how the necessary changes were made by IPIX to remove all known adverse effects to help get B to phase 3 let’s an investor know it’s in good hands. AJMO. GL
“One of the holy grails of medicine is to come up with a stable, simple and easy to synthesize organic molecule, one that could be taken orally as a pill, and would function like a protein itself. This truly is one of the great holy grails of pharmaceutical research. The technology that Bill DeGrado and Mick Klein have developed achieves exactly this, using a variety of computational algorithms to mathematically design compounds which mimic the activity of proteins themselves. These compounds can be polymers, which are larger compounds that can be used as materials, and oligomers and small molecules, which can be used as drugs. Thus, biomimetics”.
Know the history
